For US Healthcare Professionals
SEARCH
ORDER GSK FLU
FLU AND COVID-19
KNOW THE FACTS
ABOUT FLU VACCINATION
DURING COVID-19
For the upcoming influenza season, influenza vaccination will be more important than ever to reduce the impact of respiratory illnesses in the population and resulting burdens on the healthcare system during the COVID-19 pandemic.¹ However,
vaccination rates across the country are plummeting according to one news source—in some areas such as New York City, by as much as
91%.²
Here’s what the Centers for Disease Control and Prevention (CDC) has to say about flu vaccination during COVID-19.
Take Advantage of Every Opportunity to Vaccinate Against the Flu
- Routine vaccination is an essential preventive care service for children, adolescents, and adults (including pregnant women) that should not be delayed because of the COVID-19 pandemic.¹
- Wellness visits can be useful for assessing your patients’ vaccination status. Use this time to vaccinate your appropriate patients against the flu.¹
Best Practices for Administering Flu Vaccine During COVID-19
Be Prepared
Make sure to check for
vaccination status among
patients at every visit¹
Be Proactive
Identify patients who
have missed well visits and
schedule appointments¹
Be Persistent
Utilize reminder and recall
systems and electronic health records to check for patients who
may have missed vaccinations¹
Helpful Resources About Flu and COVID-19
Here are some resources to help you learn more about vaccinating against the flu during COVID-19:
Reduce the burden of respiratory illness this flu season with these CDC guidelines
Interim Guidance for Routine and Influenza Immunization Services During the COVID-19 Pandemic
Make sure to vaccinate all appropriate patients 6 months of age or older
Who Should and Who Should NOT Get Vaccinated
Keep up to date with all vaccinations
Healthcare Providers and Professionals | Vaccine Administration Protocols | CDC
Implement effective strategies for catch-up vaccination
Catch-up Immunization Schedule | CDC
Get your clinic ready for COVID-19 with these tips
Coronavirus Disease 2019 (COVID-19)
Seek guidance from CDC for opening satellite, temporary, off-site clinics
Guidance for Planning Vaccination Clinics | CDC
Refer to this checklist for best practices for temporary or off-site vaccination clinics
https://www.izsummitpartners.org/content/uploads/2019/02/off-site-vaccination-clinic-checklist.pdf
Take advantage of available patient education resources when applicable
Print Materials | CDC
Explore GSK flu vaccines
to help simplify procurement and inventory management and help realize every vaccination opportunity.

Indication for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT
Important Safety Information for FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT
FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT are vaccines indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccines. FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT are approved for use in persons aged 6 months and older.
- Do not administer FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
- If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT should be based on careful consideration of the potential benefits and risks
- Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUARIX QUADRIVALENT and FLULAVAL QUADRIVALENT. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
- If FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
- In clinical trials with FLUARIX QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common systemic adverse reactions were muscle aches, headache, and fatigue. In children 6 through 35 months of age, the most common solicited local adverse reactions were pain and redness and the most common systemic adverse reactions were irritability, loss of appetite, and drowsiness. In children 3 through 17 years of age, the solicited local adverse reactions were pain, redness, and swelling. In children 3 through 5 years of age, the most common systemic adverse reactions were drowsiness, irritability, and loss of appetite. In children 6 through 17 years of age, the most common systemic adverse reactions were fatigue, muscle aches, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLUARIX QUADRIVALENT for other potential adverse reactions and events)
- In clinical trials with FLULAVAL QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were muscle aches, headache, fatigue, and arthralgia. In children 6 through 35 months of age, the most common solicited local adverse reaction was pain and the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 3 through 17 years of age, the most common solicited local adverse reaction was pain. In children 3 through 4 years of age, the most common solicited systemic adverse reactions were irritability, drowsiness, and loss of appetite. In children 5 through 17 years of age, the most common solicited systemic adverse reactions were muscle aches, fatigue, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLULAVAL QUADRIVALENT for other potential adverse reactions and events)
- Vaccination with FLUARIX QUADRIVALENT or FLULAVAL QUADRIVALENT may not result in protection in all vaccine recipients
Please see full Prescribing Information for FLUARIX QUADRIVALENT.
Please see full Prescribing Information for FLULAVAL QUADRIVALENT.
View all
References.
Chat with GSK
To report SUSPECTED ADVERSE REACTIONS, contact GSK at 1-888-825-5249 or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch. You are encouraged to report vaccine adverse events to the US Department of Health and Human Services. Visit
www.vaers.hhs.gov to file a report, or call 1-800-822-7967.
GSK Vaccines Access Program
Help provide eligible patients with access to GSK vaccines through the GSK Vaccines Access Program.
Participate in the Program
Trademarks are owned by or licensed to the GSK group of companies.

This website is funded and developed by GSK.
This site is intended for US healthcare professionals only.
©2020 GSK or licensor.
FLQWCNT200002 September 2020